PMID: 11328308May 1, 2001Paper

Association between the SDF1-3'A allele and high levels of CD34(+) progenitor cells mobilized into peripheral blood in humans

British Journal of Haematology
L BenboubkerJ Domenech

Abstract

Some patients unexpectedly fail to mobilize sufficient numbers of haematopoietic progenitor cells (HPCs) into the peripheral blood for autologous transplantation. Considering the important role of the chemokine stromal cell-derived factor 1 (SDF-1) in HPC homing, we investigated a possible relationship between SDF1 gene polymorphism and HPC mobilization capacity in 63 patients with malignancy. Some 67% of the good mobilizers (> or = 50 CD34(+) cells/microl) and only 36% of the intermediate/poor mobilizers were SDF1-3'A allele carriers (P = 0.032). In multivariate analysis, the presence of the SDF1-3'A allele was the only factor predictive of good CD34(+) cell mobilization (P = 0.025). This is the first report showing the involvement of genetic factors for HPC mobilization in humans and suggests a significant role for SDF-1 in this process.

Citations

Mar 7, 2002·Current Opinion in Oncology·Donna E Reece
Feb 6, 2010·Expert Opinion on Biological Therapy·Marc-Michael Zaruba, Wolfgang-Michael Franz
Oct 25, 2011·Transfusion clinique et biologique : journal de la Société française de transfusion sanguine·F BijouF Nicolini
Dec 7, 2007·Cytokine·Giorgio GhilardiRoberto Scorza
May 20, 2015·Cytokine·Katarzyna Bogunia-KubikUNKNOWN POLISH DONOR–RECIPIENT STUDY GROUP
Oct 20, 2012·European Journal of Haematology·Fan-Chen KuWen-Li Hwang
Jun 28, 2005·Cancer Letters·Mahboobeh RazmkhahAbbas Ghaderi
Apr 1, 2014·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Anna Szmigielska-KaplonAgnieszka Wierzbowska
Jul 28, 2009·Clinical Science·Richard M CubbonStephen B Wheatcroft
Jul 31, 2013·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Juliane LenkChristian Thiede
May 29, 2013·Cytokine·Grzegorz MazurKatarzyna Bogunia-Kubik
Aug 19, 2014·Cytokine & Growth Factor Reviews·Linda J Bendall, Kenneth F Bradstock
Aug 5, 2006·Journal of Cellular Biochemistry·Bruno NerviJohn F DiPersio
Jul 5, 2006·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Florence DommangeUNKNOWN GOELAMS Study Group
Nov 19, 2010·Expert Review of Hematology·Lloyd E Damon, Lauren E Damon
Aug 13, 2011·Bulletin du cancer·Christian ChabannonAnne-Marie Imbert

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.